

Practitioner's Docket No. **MPI00-5350MNICN1M**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Fraser, Christopher C, et al		
Application No.:	10/741,790	Group No.:	1646
Filed:	December 19, 2003	Examiner:	Not Yet Assigned
For:	NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES		

**Mail Stop Amendment**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**AMENDMENT TRANSMITTAL**

1. Transmitted herewith for this application are:
  - a. This Amendment Transmittal (2 pages – in duplicate);
  - b. Second Preliminary Amendment (11 pages);
  - c. Associate Power of Attorney (2 pages) and Appendix A – Statement of Limited Recognition under 37 CFR §10.9(b) for Mario Cloutier (1 page);
  - d. Statement of Limited Recognition under 37 CFR §10.9(b) for Mario Cloutier (1 page);
  - e. Return Receipt Postcard.

**STATUS**

2. Applicant is other than a small entity.

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No.

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office

  
Signature

Sean Hunziker

(type or print name of person certifying)

Date: October 29, 2004

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**FEE FOR CLAIMS**

3. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)			(Col. 2)		(Col. 3)	OTHER THAN A SMALL ENTITY		
Claims Remaining After Amendment			Highest No. Previously Paid For		Present Extra	Rate		Addit. Fee
Total	20	Minus	20	=	0	\$18.00	=	\$0.00
Indep.	3	Minus	3	=	0	\$88.00	=	\$0.00
First Presentation of Multiple Dependent Claims			0			\$300.00	=	\$0.00
						Total Addit. Fee		\$0.00

Total additional fee for claims required \$0.00

**FEE DEFICIENCY**

5. Applicant believes there is no fee due with this request. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

6. Correspondence Address

Direct all future correspondence to:

Customer Number 30405


OR

Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139

October 29, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Mario Cloutier

Limited Recognition Under 37 C.F.R. §10.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820